Acute-Onset Endophthalmitis Caused by Alloiococcus otitidis following a Dexamethasone Intravitreal Implant

• Published in: Case reports in ophthalmology Vol. 4; no. 1; pp. 37 - 41
• Main Authors: Marchino, Tizana, Vela, José I., Bassaganyas, Francisca, Sánchez, Saskia, Buil, José A.
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 07.03.2013; Karger Publishers
• Subjects: Alloiococcus otitidis; Dexamethasone implant; Endophthalmitis; Ozurdex; Published: March 2013; Endophthalmitis; Alloiococcus otitidis; Dexamethasone implant; Ozurdex
• ISSN: 1663-2699; 1663-2699
• DOI: 10.1159/000348809

Purpose: To report the first case of acute endophthalmitis caused by Alloiococcus otitidis after a dexamethasone intravitreal implant. Methods: A 74-year-old female was treated with intravitreal Ozurdex® in her left eye for central retinal vein occlusion (CRVO). Best-corrected visual acuity (BCVA) in the eye was 4/20. Intravitreal injection was uneventful. At 48 h after injection, she developed ocular pain and visual acuity had dropped to light perception. Endophthalmitis associated with intravitreal injection was suspected. Results: The patient did not show a favorable clinical response following systemic, intravitreal, and topical fortified antibiotics. We then performed a vitreous biopsy and removed the Ozurdex implant by pars plana vitrectomy. A vitreous culture was positive for A. otitidis. At the 2-month follow up, no inflammation was observed, but due to CRVO and probably aggravated by endophthalmitis, the fundus showed macular fibrosis. The final BCVA was finger counting at 30 cm in her left eye. Conclusions: In cases of an intravitreal implant associated with endophthalmitis, we recommend removal of the device because it may act as a permanent reservoir of organisms if it remains in the vitreous cavity.